Simponi subcutaneous injection is indicated for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Janssen Biotech discovered and developed Simponi as a treatment for inflammatory autoimmune diseases involving TNF alpha such as rheumatoid arthritis which was first approved in the US and Europe in 2009.
After receiving Japanese approval, Mitsubishi Tanabe and Janssen Pharmaceutical stated co-marketing Simponi in 2011.